Drug trial for chronic hives withdrawn before starting
NCT ID NCT06795373
Summary
This study aimed to test if the drug ritlecitinib is safe and effective for treating chronic spontaneous urticaria (CSU), a condition causing long-lasting hives and itching. Eligible adults with CSU not well-controlled by standard antihistamines would have taken the oral drug daily for 12 weeks while tracking their symptoms. The trial was withdrawn before any participants were enrolled.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC SPONTANEOUS URTICARIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Icahn School of Medicine at Mount Sinai
New York, New York, 10029, United States
Conditions
Explore the condition pages connected to this study.